AR089931A1 - Composiciones farmaceuticas que contienen dimetilfumarato - Google Patents

Composiciones farmaceuticas que contienen dimetilfumarato

Info

Publication number
AR089931A1
AR089931A1 ARP130100385A ARP130100385A AR089931A1 AR 089931 A1 AR089931 A1 AR 089931A1 AR P130100385 A ARP130100385 A AR P130100385A AR P130100385 A ARP130100385 A AR P130100385A AR 089931 A1 AR089931 A1 AR 089931A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
compositions containing
containing dimethylfumarate
dimethylfumarate
dimethyl fumarate
Prior art date
Application number
ARP130100385A
Other languages
English (en)
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48947963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089931(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of AR089931A1 publication Critical patent/AR089931A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Reivindicación 1: Una composición que comprende dimetilfumarato y uno o varios excipientes, en donde la cantidad total de dimetilfumarato en la composición varía de aproximadamente el 43% p/p a aproximadamente el 95% p/p.
ARP130100385A 2012-02-07 2013-02-07 Composiciones farmaceuticas que contienen dimetilfumarato AR089931A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261596202P 2012-02-07 2012-02-07
US201261625621P 2012-04-17 2012-04-17
US201261723048P 2012-11-06 2012-11-06

Publications (1)

Publication Number Publication Date
AR089931A1 true AR089931A1 (es) 2014-10-01

Family

ID=48947963

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100385A AR089931A1 (es) 2012-02-07 2013-02-07 Composiciones farmaceuticas que contienen dimetilfumarato

Country Status (24)

Country Link
US (7) US20130216615A1 (es)
EP (1) EP2811994A4 (es)
JP (4) JP6189333B2 (es)
KR (1) KR102105217B1 (es)
CN (5) CN113244185A (es)
AR (1) AR089931A1 (es)
AU (6) AU2013203445C1 (es)
BR (1) BR112014019462B1 (es)
CA (1) CA2862885C (es)
CL (1) CL2014002077A1 (es)
CO (1) CO7141407A2 (es)
EA (1) EA038152B1 (es)
EC (1) ECSP14014870A (es)
HK (1) HK1202261A1 (es)
IL (2) IL233833B (es)
MX (1) MX370785B (es)
NI (1) NI201400086A (es)
NZ (1) NZ627980A (es)
PE (1) PE20150092A1 (es)
PH (1) PH12014501750A1 (es)
SG (1) SG11201404705YA (es)
TW (4) TWI676475B (es)
WO (1) WO2013119677A1 (es)
ZA (1) ZA201405511B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004010531T2 (de) 2003-09-09 2008-07-03 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
PL2801355T3 (pl) 2004-10-08 2015-10-30 Fwp Ip Aps Kompozycje farmaceutycznie o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
DK2139467T3 (da) * 2007-02-08 2017-01-02 Biogen Ma Inc Neurobeskyttelse i demyelinisationssygdomme
CA2730478C (en) 2008-08-19 2014-04-15 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate
SI2718257T1 (en) 2011-06-08 2018-04-30 Biogen Ma Inc. PROCEDURE FOR PREPARATION OF HIGH QUALITY CRYSTALINIC DIMETHY OF FUMARAT
JP6189333B2 (ja) * 2012-02-07 2017-08-30 バイオジェン エムエー インコーポレーテッド フマル酸ジメチルを含有する医薬組成物
JP2015526477A (ja) 2012-08-22 2015-09-10 ゼノポート，インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
JP2015527372A (ja) * 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
CN105142628A (zh) 2012-12-21 2015-12-09 比奥根玛公司 氘取代的富马酸盐衍生物
NZ723459A (en) 2013-03-14 2017-12-22 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various diseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2014143146A1 (en) * 2013-03-15 2014-09-18 Xenoport, Inc. Methods of administering monomethyl fumarate
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
WO2015086467A1 (en) * 2013-12-12 2015-06-18 Almirall, S.A. Pharmaceutical compositions comprising dimethyl fumarate
WO2015089420A1 (en) * 2013-12-13 2015-06-18 Biogen Idec Ma Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
AU2015222880B2 (en) 2014-02-28 2016-11-24 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
MA51730A (fr) 2014-03-14 2020-12-16 Biogen Ma Inc Fumarate de diméthyle et régimes de vaccination
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016057133A1 (en) * 2014-10-08 2016-04-14 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
CA2965449C (en) * 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
MA40990A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
CN104490849A (zh) * 2014-11-24 2015-04-08 广东东阳光药业有限公司 一种高密度的富马酸二甲酯肠溶颗粒及其制备方法
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
WO2016126540A1 (en) * 2015-02-02 2016-08-11 Enspire Group LLC Stabilized dialkyl fumarate compositions
KR102487136B1 (ko) * 2015-02-08 2023-01-10 엘커메스 파마 아일랜드 리미티드 모노메틸푸마레이트 전구약물 조성물
WO2016147108A1 (en) * 2015-03-17 2016-09-22 Hetero Research Foundation Pharmaceutical compositions of dimethyl fumarate
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
US10085961B2 (en) 2015-06-01 2018-10-02 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
JP2018517735A (ja) 2015-06-17 2018-07-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． フマル酸ジメチル粒子及びそれらの医薬組成物
WO2017056107A1 (en) * 2015-09-28 2017-04-06 Natco Pharma Ltd Pharmaceutical compositions of dimethyl fumarate
RU2018118603A (ru) * 2015-10-28 2019-11-28 Сан Фармасьютикал Индастриз Лимитед Фармацевтические композиции диметилфумарата
PL3397247T3 (pl) * 2015-12-31 2023-09-18 Zakłady Farmaceutyczne Polpharma Sa Sposób wytwarzania powlekanego dojelitowo granulatu zawierającego fumaran dimetylu
EP3407873A1 (en) * 2016-01-28 2018-12-05 Zaklady Farmaceutyczne Polpharma SA Process for preparation of a granulate comprising dimethyl fumarate
US11033509B2 (en) * 2016-02-11 2021-06-15 Biogen Ma Inc. Pharmaceutical bead formulations comprising dimethyl fumarate
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
TR201616998A1 (en) 2016-11-23 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi DELAYED RELEASE DOSING FORMS WITH DIMETHYL FUMARATE
WO2018170319A1 (en) * 2017-03-17 2018-09-20 Vitalis Llc Compositions and methods for treating multiple sclerosis
JP7308763B2 (ja) 2017-06-23 2023-07-14 アルミラル・ソシエダッド・アノニマ フマル酸ジメチルを含む医薬組成物
WO2020055739A1 (en) * 2018-09-10 2020-03-19 Vitalis Llc Fumaric acid compositions with increased bioavailability and reduced side effects
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
TR201818293A2 (tr) 2018-11-30 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
WO2021144478A2 (en) 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
AU2022285951A1 (en) * 2021-06-04 2024-01-04 Zim Laboratories Limited Delayed release compositions of dimethyl fumarate
US20240010618A1 (en) 2021-12-23 2024-01-11 Glenmark Lofe Science Limited Process for the preparation of brivaracetam

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153927A (en) 1966-08-25 1969-06-04 Wilhelm Hoerrmann Medicinal Composition Suitable For Treating Diseases Of The Retina
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US5484610A (en) 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
DE19814358C2 (de) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US6537584B1 (en) 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
WO2003004001A1 (en) 2001-07-06 2003-01-16 Lifecycle Pharma A/S Controlled agglomeration
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
DE10214031A1 (de) 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
EP1603540A2 (en) * 2003-03-14 2005-12-14 Nirmal Mulye A process for preparing sustained release tablets
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
DE602004010531T2 (de) 2003-09-09 2008-07-03 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
PL2801355T3 (pl) * 2004-10-08 2015-10-30 Fwp Ip Aps Kompozycje farmaceutycznie o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
WO2007006307A2 (en) * 2005-07-07 2007-01-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
EP1951206A1 (en) 2005-10-07 2008-08-06 Aditech Pharma AB Controlled release pharmaceutical compositions comprising a fumaric acid ester
EP1940382A2 (en) 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
CA2635594A1 (en) * 2005-12-30 2007-07-12 Advancis Pharmaceutical Corporation Gastric release pulse system for drug delivery
US20090018175A1 (en) * 2007-04-25 2009-01-15 Itamar Kanari Pharmaceutical excipient complex
WO2009085832A2 (en) * 2007-12-21 2009-07-09 Mcneil-Ppc, Inc. Manufacture of tablet
CA2724594A1 (en) * 2008-05-20 2009-11-26 John R. Wetterau Niacin and nsaid combination therapy
CA2730478C (en) 2008-08-19 2014-04-15 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate
US20120034274A1 (en) 2009-01-09 2012-02-09 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
ES2411972T5 (es) 2009-01-09 2021-10-27 Fwp Ip Aps Formulación farmacéutica que comprende uno o más ésteres de ácido fumárico en una matriz de erosión
EP2424357A4 (en) 2009-04-29 2012-10-10 Biogen Idec Inc TREATMENT OF NERVOUS GENERATION AND NERVE IGNITION
US20100285164A1 (en) 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
EP2533634B1 (en) * 2010-02-12 2015-10-21 Biogen MA Inc. Neuroprotection in demyelinating diseases
JP6189333B2 (ja) * 2012-02-07 2017-08-30 バイオジェン エムエー インコーポレーテッド フマル酸ジメチルを含有する医薬組成物

Also Published As

Publication number Publication date
US20190358190A1 (en) 2019-11-28
TWI697338B (zh) 2020-07-01
BR112014019462A8 (pt) 2017-07-11
EP2811994A1 (en) 2014-12-17
KR102105217B1 (ko) 2020-06-01
AU2018260937A1 (en) 2018-12-06
US20150209318A1 (en) 2015-07-30
CL2014002077A1 (es) 2014-12-05
CA2862885C (en) 2020-06-02
IL290378A (en) 2022-04-01
CN114146080A (zh) 2022-03-08
TW202231268A (zh) 2022-08-16
PH12014501750A1 (en) 2014-11-10
US20180185319A1 (en) 2018-07-05
JP2022024048A (ja) 2022-02-08
AU2013203445A1 (en) 2013-08-22
MX2014009469A (es) 2014-09-22
ECSP14014870A (es) 2015-09-30
BR112014019462A2 (es) 2017-06-20
MX370785B (es) 2020-01-06
CA2862885A1 (en) 2013-08-15
WO2013119677A1 (en) 2013-08-15
EA038152B1 (ru) 2021-07-14
CN104220061A (zh) 2014-12-17
AU2017208367A1 (en) 2017-08-17
TW201818925A (zh) 2018-06-01
EP2811994A4 (en) 2016-01-13
US20180263946A1 (en) 2018-09-20
AU2013204286A1 (en) 2013-08-22
EA201491484A1 (ru) 2015-02-27
AU2020244395B2 (en) 2022-11-24
JP2019059732A (ja) 2019-04-18
CN114146081A (zh) 2022-03-08
AU2017200394B2 (en) 2018-12-06
ZA201405511B (en) 2022-12-21
HK1202261A1 (en) 2015-09-25
SG11201404705YA (en) 2014-10-30
JP6430598B2 (ja) 2018-11-28
IL290378B1 (en) 2023-01-01
US20130216615A1 (en) 2013-08-22
TW202102205A (zh) 2021-01-16
AU2013203445C1 (en) 2017-04-20
AU2017200394A1 (en) 2017-02-09
AU2020244395A1 (en) 2020-10-29
CO7141407A2 (es) 2014-12-12
JP2015506377A (ja) 2015-03-02
NI201400086A (es) 2015-01-08
KR20150001726A (ko) 2015-01-06
JP6189333B2 (ja) 2017-08-30
AU2013203445B2 (en) 2016-10-20
IL233833B (en) 2022-03-01
IL233833A0 (en) 2014-09-30
CN114146079A (zh) 2022-03-08
TWI676475B (zh) 2019-11-11
AU2018260937B2 (en) 2020-07-02
BR112014019462B1 (pt) 2022-03-22
NZ627980A (en) 2016-12-23
TW201345520A (zh) 2013-11-16
US20130295169A1 (en) 2013-11-07
US20200222354A1 (en) 2020-07-16
IL290378B2 (en) 2023-05-01
CN113244185A (zh) 2021-08-13
AU2013204286B2 (en) 2017-05-11
PE20150092A1 (es) 2015-02-06
JP2017222705A (ja) 2017-12-21

Similar Documents

Publication Publication Date Title
AR089931A1 (es) Composiciones farmaceuticas que contienen dimetilfumarato
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CO7111285A2 (es) Composiciones pesticidas y procesos relacionados con ellas
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
UY33937A (es) Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
UY34571A (es) Composiciones herbicidas que contienen bentazón y el inhibidor als y el inhibidor accasa.
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
CO7160079A2 (es) Composiciones líquidas de racecadotrillo
CL2015002897A1 (es) Inhibidores de bace1
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
BR112014025041B8 (pt) Composição farmacêutica
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
CO2017006898A2 (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
BR112014032759A2 (pt) composições lipídicas de racecadotril
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
FR2977256B1 (fr) Compositions de 2,4,4,4-tetrafluorobut-1-ene et de cis-1,1,1,4,4,4-hexafluorobut-2-ene
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
CL2015000848A1 (es) Uso de un compuesto de propilmetilfenol, o una composición que lo comprende, para producir una composición farmacéutica y/o nutracéutica para el tratamiento y/o profilaxis de la anemia infecciosa del salmón (isa) (divisional sol. n° 2654-12).
CR20150275A (es) Composición de difenidol de liberación prolongada

Legal Events

Date Code Title Description
FC Refusal